Renal Cell Carcinoma (RCC)/Proximal Nephrogenic Antigen [MD368R]

Anti-renal cell carcinoma (RCC) recognizes a 200 kD glycoprotein localized in the brush border of the proximal renal tubule. This antibody immunoreacts with approximately 90% of primary renal cell carcinomas and approximately 85% of metastatic renal cell carcinomas. Therefore, anti-RCC is a reliable tool for differentiating primary or metastatic renal cell carcinoma from non-renal tumors. It may be utilized as a marker for the differential diagnosis of eosinophilic renal tumors-granular variant of renal cell carcinoma, chromophobe renal cell carcinoma, and oncocytoma. Other tumors that may react with this antibody are parathyroid adenoma and an occasional breast carcinoma. Nephroblastoma, oncocytoma, mesoblastic nephroma, transitional cell carcinoma, and angiomyolipoma are not labeled with this antibody.